Voyager Therapeutics has been granted a patent for compositions and methods involving polynucleotides encoding AADC for treating Parkinson’s Disease. The patent includes a specific polynucleotide sequence and requirements for the length of inverted terminal repeats. GlobalData’s report on Voyager Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Voyager Therapeutics, Adeno-associated virus vectors was a key innovation area identified from patents. Voyager Therapeutics's grant share as of May 2024 was 13%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11975056B2) discloses a polynucleotide encoding an aromatic L-amino acid decarboxylase (AADC) protein, with specific sequences and structural elements outlined in the claims. The polynucleotide includes inverted terminal repeats (ITRs) of at least 130 nucleotides in length at both the 5' and 3' ends, along with various other specific regions such as cytomegalovirus (CMV) sequences, immediate early 1 (IE1) sequences, human beta globin (HB) sequences, and a poly(A) signal sequence region. The patent also covers a recombinant adeno-associated virus (rAAV) containing the AAV vector genome with the polynucleotide, potentially useful for increasing AADC protein levels in subjects, particularly those with Parkinson's Disease.
Furthermore, the patent includes claims related to the specific lengths and compositions of the various regions within the polynucleotide, as well as the types of AAV capsids that can be used in the rAAV. Additionally, a pharmaceutical composition comprising the rAAV and a pharmaceutically acceptable excipient is detailed, with specific requirements for the percentage of rAAV vectors containing the AAV vector genome. The patent also outlines a method for increasing AADC protein levels in subjects, particularly those with Parkinson's Disease, by administering the pharmaceutical composition, which may also have potential benefits for treating insomnia or reducing periods of dyskinesia in the subject.
To know more about GlobalData’s detailed insights on Voyager Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
